REJUVTIMELESS HEALTH & AESTHETICS
ENES
(813) 563-2799REQUEST A CONSULTATION
HOME / JOURNAL / NAD+ IV DRIPS: WHAT THE EVIDENCE REALLY SHOWS
Journal

NAD+ IV Drips: What the Evidence Really Shows

2026-10-21
Close-up of an IV drip chamber with a droplet forming, backlit by warm window light.

NAD+ IV drips are one of the most popular wellness treatments in the country. They're promoted for energy, focus, recovery, "cellular repair" and slower aging. Celebrities post about them, and many Tampa Bay wellness clinics offer them.

The science behind NAD+ is real. The evidence that an NAD+ drip makes you healthier is not there yet. As of October 2026, no randomized, placebo-controlled trial has shown that IV NAD+ improves energy, cognition, aging or any other outcome patients care about. A 2026 review of IV NAD+ research called the evidence "preliminary and insufficient to support routine clinical or wellness use."

That doesn't mean everyone who feels better after a drip is imagining it. It means you should know what's proven, what isn't, and what to ask before you sit in the chair. This article is the skeptical companion to our NAD+ science overview, which covers the basic biology.

Table of Contents

  1. Why NAD+ got so popular
  2. The mouse-to-human gap
  3. What actually happens when NAD+ goes into a vein
  4. What the human studies of IV NAD+ show
  5. Oral precursors NR and NMN have better data
  6. Side effects of NAD+ infusions
  7. Is NAD+ for injection FDA-approved
  8. The case for and against trying it
  9. Frequently asked questions
  10. The bottom line

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. Cells need it to turn food into usable energy. Enzymes involved in DNA repair and stress responses, such as sirtuins and PARPs, use it too. The pitch is easy to follow. NAD+ declines with age, so topping it up should slow aging.

That pitch has two weak spots.

The first is the claim that NAD+ falls with age in a way a drip could fix. A May 2026 study in Nature Metabolism measured whole-blood NAD+ in seven independent human cohorts using a carefully validated method. Levels were "remarkably stable with age and across lifestyle interventions." They did rise with nicotinamide riboside supplements. The authors concluded that blood NAD+ is not a useful marker of aging. NAD+ in specific tissues, like muscle or brain, may still change with age. But the popular claim that NAD+ steadily drains out of your blood as you age is not supported by this data.

The second weak spot is the leap from "this molecule matters" to "infusing this molecule helps." Those are different questions, and most of the hype skips the second one.

The mouse-to-human gap

Much of the excitement comes from animal research, and the mouse data are genuinely striking.

  • In a 2016 Science paper, the NAD+ precursor nicotinamide riboside (NR) rejuvenated muscle stem cells in aged mice and increased mouse life span.
  • In a 2016 Cell Metabolism study, a year of oral NMN in normally aging mice reduced age-related weight gain and improved energy metabolism, physical activity, insulin sensitivity and eye function.

As a nutrition researcher at Washington University in St. Louis told NPR in May 2026: "In rodents and mice — not in humans — NAD+ is miraculous."

Lab mice are studied with controlled diets in controlled conditions, and results often fail to carry over to people. That is not a knock on the science. It is the reason human trials exist. And for IV NAD+ specifically, the human trials mostly haven't been done.

What actually happens when NAD+ goes into a vein

The best-known human study of infused NAD+ is a 2019 pilot from Australia published in Frontiers in Aging Neuroscience. Researchers infused NAD+ slowly over six hours and measured it in blood and urine. They found:

  • For the first two hours, plasma NAD+ did not rise at all. The infused NAD+ was "rapidly and completely removed" from the blood.
  • The breakdown products in the blood fit enzymes that cleave NAD+ outside cells.
  • Some NAD+ and its byproduct methylnicotinamide showed up in the urine by six hours.

In plain English, much of an IV dose appears to be broken down or cleared quickly. Whether meaningful amounts reach the inside of cells, where NAD+ does its work, is still unknown. The chief science officer of a national infusion chain told NPR that her group's early human data suggest NAD+ infusions are "very inefficient" at raising levels inside cells. She noted that NAD+ has "no easy door" into the cell from the bloodstream.

This is a big reason scientists focus on precursors such as NR and NMN. Cells can take these up and build their own NAD+.

What the human studies of IV NAD+ show

The short answer is very little, and none of it shows a clinical benefit.

  • A 2026 systematic review in Ageing Research Reviews found 33 human intervention studies of NAD-related compounds, 28 of them randomized. Not one was an outcomes trial of IV or intramuscular NAD+ for anti-aging or wellness. The only IV NAD+ study it found was the 2019 pharmacokinetic pilot, which had no clinical outcomes.
  • A 2026 narrative review in Frontiers in Aging looked at human data on IV NAD+ and IV precursors. It described the evidence as "sparse," made up mostly of "small uncontrolled studies, observational investigations, and isolated case reports." It concluded that robust conclusions on efficacy, dosing and long-term safety "cannot currently be established."
  • A 2026 retrospective study from a commercial infusion chain compared four days of IV NAD+ with four days of IV NR in its own clients. It was designed to assess tolerability, not benefit, and its authors were employed by the company.

The common claims of more energy, sharper focus, better recovery, addiction support and slower aging come from marketing, testimonials and animal biology. They don't come from controlled human trials of NAD+ infusions.

Oral precursors NR and NMN have better data

If you're comparing an NAD+ drip with an NR or NMN supplement, the pills actually have more human research behind them. The results are mixed, though.

What they reliably do

Oral NR and NMN raise NAD+-related markers in blood. A 2018 crossover trial in Nature Communications found NR was well tolerated and raised NAD+ in healthy middle-aged and older adults. The 2026 Ageing Research Reviews analysis found this kind of "target engagement" fairly consistent across trials.

What they have not reliably done

They have not reliably improved the outcomes people buy them for. Results on function, metabolism and blood vessels have been "heterogeneous and often null or endpoint-specific."

  • Positive signal: In a 10-week randomized trial in Science (2021), NMN improved muscle insulin sensitivity in postmenopausal women with prediabetes and overweight or obesity.
  • Null result: In a 12-week randomized trial in obese men, high-dose NR did not improve insulin sensitivity, energy expenditure or body composition (American Journal of Clinical Nutrition, 2018).
  • A cautionary result: NPR's May 2026 report cited Parkinson's disease as one of the promising areas. Then, on October 8, 2026, JAMA published NOPARK, a 52-week phase 3 trial in 410 people with early Parkinson's disease. Oral NR did not help. Motor and non-motor scores actually worsened slightly more on NR than on placebo.

NOPARK is the clearest example yet of a promising NAD+ story meeting a large, rigorous human trial and failing. That doesn't mean every use will fail. It does mean "it works in mice and small pilots" is not enough.

Side effects of NAD+ infusions

Patients who have had a fast NAD+ drip often describe how it feels. The published reports match those descriptions.

  • Common during infusion: nausea, stomach cramping, flushing, and chest tightness or pressure. A 2026 review listed nausea, cramping, flushing and chest discomfort as the reported adverse effects.
  • Rate matters: In the 2026 retrospective study, people getting IV NAD+ reported moderate to severe stomach symptoms, a faster heart rate and chest pressure. Those symptoms led to longer infusions, averaging 97 minutes versus 37 minutes for IV NR. Symptoms resolved once the infusion ended.
  • Product quality matters: In 2024, the FDA warned that some compounders were using food-grade NAD+ to make IV products. It received reports of "severe chills, shaking, vomiting and fatigue," some needing medical treatment. Those reactions were consistent with excessive endotoxin, a bacterial contaminant.
  • Long-term safety is unknown. Some mouse studies have raised a theoretical concern that raising NAD+ could feed tumor growth. One researcher told NPR this has not been seen widely in animals or at all in humans, but multi-year data don't exist.

Is NAD+ for injection FDA-approved

No. There is no FDA-approved NAD+ drug for injection or infusion, for anti-aging or anything else. NAD+ IVs come from compounding pharmacies.

The legal picture is more nuanced than "illegal" or "approved." On the FDA's list of bulk substances nominated for 503A compounding (updated May 14, 2026), nicotinamide adenine dinucleotide (NAD) sits in Category 1, meaning it is under evaluation. The FDA says it does not intend to take action against compounders using Category 1 substances while the evaluation is pending, as long as they meet the conditions in its guidance. The FDA can change that if new safety information emerges.

So a licensed pharmacy can generally compound NAD+ for an individual prescription today. That is not the same as the FDA finding NAD+ safe or effective. It also doesn't cover the quality of every product. The 2024 endotoxin warning shows why sourcing matters.

The case for and against trying it

The case for

  • NAD+ biology is legitimate science, studied by serious researchers.
  • Short-term tolerability at a slow infusion rate looks acceptable in the limited data.
  • Some people report feeling better. The infusion-industry scientist quoted by NPR argued that this signal deserves study rather than dismissal.
  • For people who want to try it, a supervised IV with a known pharmacy source is safer than unregulated injectables.

The case against

  • No controlled human trial shows a clinical benefit from IV NAD+.
  • Pharmacokinetic data suggest much of the dose is broken down quickly, outside cells.
  • Oral precursors have more human data, and even they have mostly disappointed on hard outcomes.
  • Infusions can be uncomfortable, take time, and carry the usual risks of IV access and product quality.
  • The things with the strongest evidence for energy and healthy aging are not in an IV bag. That means sleep, aerobic fitness, strength training and managing blood pressure and blood sugar. Our articles on Zone 2 cardio and evening routines that support sleep and recovery are a better starting point.

Our take

NAD+ IV therapy is mostly hype layered on top of real science. It's not dangerous for most healthy people when given slowly with a quality product. But it's an unproven wellness choice, not a treatment for aging. If you choose it, choose it knowing that.

Frequently asked questions

Does NAD+ IV therapy actually work?

There's no controlled human evidence that it improves energy, focus, recovery or aging. Small studies show it can be infused with tolerable side effects at slow rates. That is about all that has been shown.

Is an NAD+ IV better than NMN or NR supplements?

Not based on current evidence. Oral NR and NMN have more human trials and reliably raise blood NAD+ markers. But they too have mostly failed to improve clinical outcomes, including in a large 2026 Parkinson's trial.

Why does an NAD+ drip make my chest feel tight?

Chest pressure, flushing, nausea and cramping are commonly reported, especially when NAD+ is infused quickly. In one 2026 study, symptoms resolved once the infusion ended. Tell the staff right away if you feel them.

Should I get my NAD+ level tested first?

A large 2026 study found whole-blood NAD+ stays stable with age and questioned its value as a marker of aging. A blood level is unlikely to tell you whether a drip will help. Our guide to preventive labs explains which tests are actually informative.

Who should avoid NAD+ infusions?

Anyone who is pregnant or breastfeeding, has significant heart, kidney or liver disease, has a history of cancer, or takes multiple medications should talk with a licensed provider first. There is very little safety data in these groups.

The bottom line

NAD+ is an important molecule, and research on it is worth following. NAD+ IV drips, though, are far ahead of their evidence. Human studies show the infused molecule is cleared quickly, side effects are common when it's given fast, and no controlled trial shows a meaningful benefit. If you're curious, talk it through with a licensed provider who will be honest about the uncertainty, use a quality pharmacy source and infuse slowly. Pair it with, rather than substitute it for, the basics that have the strongest evidence.

Related reading: Is BPC-157 Legal? What the FDA Panel Vote Means · Ketamine Therapy: What the Research Shows

Sources

This article is provided for general educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. NAD+ infusions are not FDA-approved for any condition; discuss your health history, medications and goals with a licensed provider before starting any IV therapy.

ASK OUR TEAM ABOUT IV THERAPY & WELLNESS INJECTIONS